2015
The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome
Tal R, Seifer DB, Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Seminars In Reproductive Medicine 2015, 33: 195-207. PMID: 26036901, DOI: 10.1055/s-0035-1552582.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeGrowth factorOvarian syndromePathophysiology of PCOSAngiogenic factor imbalanceOvarian hyperstimulation syndromeCommon endocrine disorderVascular endothelial growth factorPlatelet-derived growth factorBasic fibroblast growth factorMultiple angiogenic factorsEndothelial growth factorFibroblast growth factorHyperstimulation syndromeOvulatory dysfunctionStromal vascularityAnovulatory infertilityPolycystic ovariesEndocrine disordersReproductive ageTreatment strategiesFollicular growthOvarian angiogenesisAngiogenic factorsCorpus luteumKnowledge of ovarian reserve and reproductive choices
Azhar E, Seifer DB, Melzer K, Ahmed A, Weedon J, Minkoff H. Knowledge of ovarian reserve and reproductive choices. Journal Of Assisted Reproduction And Genetics 2015, 32: 409-415. PMID: 25596723, PMCID: PMC4363241, DOI: 10.1007/s10815-014-0415-9.Peer-Reviewed Original ResearchConceptsHealth care professionalsOvarian reserveCare professionalsMale health care professionalsMethodA cross-sectional surveyReproductive-age womenCross-sectional surveyLifestyle changesOocyte cryopreservationAnonymous questionnaireMarital statusEmbryo cryopreservationReproductive choicesNormal patternChildrenReproductive declineProfessionalsObjectiveToReproductive reservesPhysiciansDemographicsWomen
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentImpact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women
Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer DB, Anastos K, Karim R, Greenblatt RM. Impact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women. American Journal Of Reproductive Immunology 2014, 73: 273-284. PMID: 25339186, PMCID: PMC4323676, DOI: 10.1111/aji.12332.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormone levelsUninfected womenHigh AMHHIV infectionCD4 countLymphocyte countHormone levelsCurrent CD4 countImpact of CD4Total lymphocyte countCD4 T cellsHormonal contraceptive useOvarian granulosa cell functionsGranulosa cell functionPast weight lossHIV viraemiaNadir CD4Undetectable viraemiaUninfected participantsAMH levelsLow AMHOvarian functionDetectable viraemiaT cellsLarge cohortIs AMH a regulator of follicular atresia?
Seifer DB, Merhi Z. Is AMH a regulator of follicular atresia? Journal Of Assisted Reproduction And Genetics 2014, 31: 1403-1407. PMID: 25193290, PMCID: PMC4389943, DOI: 10.1007/s10815-014-0328-7.Peer-Reviewed Original ResearchConceptsFollicular atresiaNatural ovarian agingPolycystic ovary syndromeOnset of menopausePremature ovarian insufficiencyTreatment of PCOSDifferent patient populationsBasic science studiesTiming of onsetOvary syndromePatient populationOvarian agingOvarian failureHuman ovaryTreatment strategiesAMH productionOvarian insufficiencyIntraovarian regulatorsGrowth factorCellular originCritical growth factorsCancer therapyMenopauseAtresiaAMH
2013
But isn't antimüllerian hormone still better than follicle-stimulating hormone?
Toner JP, Seifer DB. But isn't antimüllerian hormone still better than follicle-stimulating hormone? Fertility And Sterility 2013, 99: e21. PMID: 23628108, DOI: 10.1016/j.fertnstert.2013.03.045.Peer-Reviewed Original ResearchWhy we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone
Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertility And Sterility 2013, 99: 1825-1830. PMID: 23548941, DOI: 10.1016/j.fertnstert.2013.03.001.Peer-Reviewed Original Research
2008
Variations in serum müllerian inhibiting substance between white, black, and Hispanic women
Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, Cohen MH, Karim R, Young MA, Minkoff H, Greenblatt RM. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertility And Sterility 2008, 92: 1674-1678. PMID: 18930217, PMCID: PMC3037722, DOI: 10.1016/j.fertnstert.2008.08.110.Peer-Reviewed Original ResearchConceptsBody mass indexHispanic womenHIV statusMass indexMulticenter prospective cohort studyWomen's Interagency HIV StudySerum MIS levelsProspective cohort studyTime pointsCohort studyDifferent time pointsMIS levelsAge-related declineHIV StudyDifferent time coursesMAIN OUTCOMESubstance levelsSerum MISWhite womenSerum samplesDifferent racial groupsWomenIndependent effectsLongitudinal studySmoking
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosisBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women
Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility And Sterility 2007, 88: 1645-1652. PMID: 17418155, PMCID: PMC2682326, DOI: 10.1016/j.fertnstert.2007.01.122.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudyEarly follicular phaseOvarian reserveInhibin BHIV infectionMIS levelsFollicular phaseHIV StudyLower inhibin B levelsReproductive agingSerum samplesHIV infection influencesInhibin B levelsMulticenter prospective studyCross-sectional studyMenstrual cycle phaseCycle phaseUninfected womenCohort studyFSH levelsMenstrual bleedingNegative womenHIV serostatusSerum markersProspective studySerum müllerian-inhibiting substance in Down's syndrome pregnancies
Seifer DB, MacLaughlin DT, Cuckle HS. Serum müllerian-inhibiting substance in Down's syndrome pregnancies. Human Reproduction 2007, 22: 1017-1020. PMID: 17218369, DOI: 10.1093/humrep/del497.Peer-Reviewed Original ResearchConceptsDown syndrome pregnanciesMüllerian-inhibiting substanceSyndrome pregnanciesUnaffected pregnanciesPregnancy-associated plasma proteinMI levelsMaternal serum levelsSerum MIS levelsWeeks of gestationCase-control studyAntenatal screening programmeAssisted reproduction techniquesMedian valueSerum levelsMIS levelsMaternal ageScreening programPregnancyDown syndromeUnaffected controlsReproduction techniquesSignificant correlationSyndromePlasma proteinsSerum
2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rateMetformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses
2003
Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women
Seifer DB, Lambert-Messerlian G, Schneyer AL. Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women. Fertility And Sterility 2003, 79: 451-452. PMID: 12568867, DOI: 10.1016/s0015-0282(02)04669-1.Peer-Reviewed Original Research
2002
DNA microarray analysis of the expression profiles of luteinized granulosa cells as a function of ovarian reserve
Chin KV, Seifer DB, Feng B, Lin Y, Shih WC. DNA microarray analysis of the expression profiles of luteinized granulosa cells as a function of ovarian reserve. Fertility And Sterility 2002, 77: 1214-1218. PMID: 12057731, DOI: 10.1016/s0015-0282(02)03114-x.Peer-Reviewed Original ResearchConceptsLuteinized granulosa cellsOvarian reserveDNA microarray analysisGranulosa cellsExpression profilesMicroarray analysisSequence tagsFertilization-embryo transferUniversity-based fertility clinicExpression profilingComplementary DNA microarray analysisGonadotropin stimulationFollicular aspirationMAIN OUTCOMEFertility clinicsWomenDNA microarraysGene expressionCellsGenesProfilingPatientsIVFClinicSignature patternsEarly follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility And Sterility 2002, 77: 468-471. PMID: 11872196, DOI: 10.1016/s0015-0282(01)03201-0.Peer-Reviewed Original ResearchConceptsOvarian responseMIS concentrationsReproductive technology cyclesGreater serum concentrationsGroup of womenOvulation inductionSerum concentrationsMaximum serumRetrospective analysisMAIN OUTCOMESubstance levelsSerum MISSerum samplesMI levelsWomenMature oocytesTechnology cyclesReproductive technologiesOocytesSerumART programsGroupIVFGreater number
2001
Contribution of diminished ovarian reserve to hypofertility associated with endometriosis.
Hock DL, Sharafi K, Dagostino L, Kemmann E, Seifer DB. Contribution of diminished ovarian reserve to hypofertility associated with endometriosis. The Journal Of Reproductive Medicine 2001, 46: 7-10. PMID: 11209637.Peer-Reviewed Original ResearchConceptsStage III/IV endometriosisStage I/II endometriosisOvarian reserveFSH levelsFertilization/embryo transferHigh E2 levelsStage of endometriosisDay 3 levelsMale factor infertilityCase-control studyAge-matched controlsFactor infertilityE2 levelsEndometriosisEmbryo transferTotal groupProgressive lossControl levelsWomenSignificant differencesE2FSHLevelsPatientsInfertility
2000
Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values?
Trout S, Seifer D. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertility And Sterility 2000, 74: 335-337. PMID: 10927054, DOI: 10.1016/s0015-0282(00)00625-7.Peer-Reviewed Original ResearchConceptsDay 3 serum FSHRecurrent pregnancy lossUnexplained recurrent pregnancy lossCauses of RPLSerum FSHPregnancy lossControl groupOvarian reserveDay 3 FSHUnexplained habitual abortionDiminished ovarian reservePresence of infertilityHistory of infertilityRetrospective comparative analysisUnexplained groupRPL groupHabitual abortionMean ageMAIN OUTCOMEFSHGreater incidenceTest groupWomenPotential roleInfertility
1999
Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone
Seifer D, Scott R, Bergh P, Abrogast L, Friedman C, Mack C, Danforth D. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertility And Sterility 1999, 72: 63-65. PMID: 10428149, DOI: 10.1016/s0015-0282(99)00193-4.Peer-Reviewed Original ResearchConceptsSerum inhibin B levelsInhibin B levelsDay 3 FSH levelsCycle cancellation rateClinical pregnancy rateSerum inhibin BOvarian reserveFSH levelsB levelsInhibin BPregnancy rateCancellation rateDay 3 follicle-stimulating hormoneDay 3 serum FSH levelsHigher cycle cancellation rateTertiary-care fertility centreNumber of ampulesSerum FSH levelsSerum FSH concentrationsFollicle-stimulating hormoneCase-control studyNumber of oocytesOvarian responsivenessFSH concentrationsGonadotropin requirements
1998
Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes
Whitacre K, Seifer D, Friedman C, Coskun S, Kennard E, Kim M, Alak B. Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes. Fertility And Sterility 1998, 70: 1015-1021. PMID: 9848288, DOI: 10.1016/s0015-0282(98)00339-2.Peer-Reviewed Original ResearchConceptsGerminal vesicle breakdownOvarian sourceNuclear maturationPatient ageGynecologic surgeryFollicular phaseLuteal phaseImmature human oocytesFinal meiotic maturationMenstrual cycle phaseYears of agePercentage of oocytesCycle phaseMetaphase II stageIVF programMenstrual cyclePatient criteriaMAIN OUTCOMEVitro maturationPatientsHuman oocytesOocyte maturationMII stageOocyte's abilityVesicle breakdown